🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

More evidence that PD(L)1 re-challenge should be avoided in renal cancer. Tivozanib+ Nivo showed no ⬆️ in efficacy v.s Tivo alone in PD(L)1 pretreated RCC pts. ⬇️ Tivo dose in study arm requires consideration. This has implications post adjuvant pembro prnewswire.com/news-releases/…

HER2: a remarkable story of precision oncology. Check this wonderful Nature review on targeting HER2 beyond breast. 👉Important to remember: now that we have an agnostic anti-HER2 drug approved (T-DXd), every adv cancer patient should get HER2 testing! nature.com/articles/s4157…

Combo Abi-olaparib better than sequential for BRCA1/2/ATM mutated #prostatecancer. Glad to see #BRCAaway published! Congrats #MahaHussain Neeraj Agarwal, MD, FASCO et al! PCF Science OncoAlert UroToday.com

Cancer Statistics 2025 are out! #prostatecancer incidence still on the rise, mortality basically flat. Get screened so you can get treatment _when needed_. #pcsm acsjournals.onlinelibrary.wiley.com/doi/epdf/10.33…

The most quoted paper in Cancer is now published: Cancer Statistics, 2025 acsjournals.onlinelibrary.wiley.com/doi/full/10.33…

🚨 Coming soon: Petros Grivas, Priyanka Chablani, MD, MS, Ali Khaki, and Karine Tawagi MD discuss Dr. Chablani's survey-based study from ASCO #GU25 on treatment sequencing after first-line #enfortumab vedotin/#pembrolizumab for locally advanced/metastatic urothelial cancer.

Survey-based study of Rx sequencing after 1L EV + P in la/mUC Priyanka Chablani, MD, MS UroToday.com #GU25 78/227 (34%) response rate, GU Med Oncs Key Q: 2nd line Rx after progression on EV + P? Favor use of: 🖊️PBC w/o combo ICI 🖊️PBC w/o ICI switch maintenance 🖊️Erda in FGFR3-alt

Survey-based Study of Treatment Sequencing After 1st Line Enfortumab Vedotin + Pembrolizumab in the Evolving Landscape of Locally Advanced or Metastatic #UrothelialCancer. Presentation by Priyanka Chablani, MD, MS UPMC. #GU25 written coverage by Zach Klaassen Georgia Cancer Center >

Proud to share that our collaborative review on Combination Therapies in Locally Advanced PC and mHSPC is now available in European Urology authors.elsevier.com/sd/article/S03…. Thanks to this wonderful team, especially to Arun Azad and Karim Fizazi. So honoured to be involved!

GU abstracts for #ASCO25! Schedule & looking forward to: 🔵PARPI in mCSPC #AMPLITUDE -HRRm analysis #TALAPRO2 -prognosis of PSA>0.2 at 6-12mo in mCSPC 🟠analysis of responders in #EV302 -novel nectin-4 ADC -ctDNA in #NIAGARA -abema in MIBC 🟣 #PDIGREE -gut checkpoint in mRCC

Dana-Farber extends our support to Former President Joe Biden and his family following news of his diagnosis with aggressive, late-stage prostate cancer. His openness brings important attention to a growing public health concern, as cases of advanced prostate cancer are on the

The 5 yr follow up for adjuvant pembro in RCC (KN564): continued benefit- DFS (5yr 52% v61% - HR0.71) OS (5yr 82% vs 88% HR0.66). Maintained KM curve separation. No subgroup stands out. 18% TRAEs. Long term tox difficult to quantify but benifits seem to outweigh risks #ASCO25

Excellent discussion on peri-op MIBC, gem/cis/durva SOC for cis-eligible, many ❓remain: ➡️ IO w/ TMT? #BRIGHT study looking post NAC ➡️ durva w/ gem/carbo? No data to support currently for cis-ineligible ➡️impact of variant histology? ➡️up or de-escalation? #MODERN #ASCO25

📢 #ASCO25 | Biomarkers in Kidney Cancer: Are We There Yet? | Review of RCC biomarker landscape: PD‑L1, TMB, ctDNA, gene expression signatures, and microbiome insights—no validated predictors yet; integrated, multimodal strategies needed. W. Kimryn Rathmell et al. Full

🌟 Brilliant presentation by Sumanta K. Pal, MD, FASCO at #ASCO25! Genomic analysis from IMmotion010👉 High KIM-1/Teff shows longer DFS with adjuvant atezolizumab vs placebo 🙌 ASCO OncoAlert KidneyCAN

EV-P is the right treatment. It’s time to learn how to really use it. #JacquelineBrown said. Wonderful discussion of novel strategies in 1L metastatic urothelial cancer. ASCO #FeaturedVoices OncoAlert SEOM Oncology Brothers

LITESPARK-004 (5-yr f/u): Belzutifan in VHL disease–associated tumors (n=61) 🎯 ORR: • RCC: 70% • CNS HB: 50% • pNETs: 90% • Retinal HB: 100% improvement (18 eyes) ➡️57% still on tx at 5 yrs 🛡️ Grade 3 TRAEs: 18% (anemia most common) 🚫 No grade 4/5 TRAEs ✅Durable

TiP: TRIPLE-SWITCH -- Ph III RCT for adding Doce to ARPIs in mCSPC and subopt PSA resp UroToday.com #ASCO25 🔷n=830 🔷Subopt PSA resp: PSA ≥0.2 ng/mL after 6-12 mos ADT, ≥4 mos ARPI 🔷1:1 cont ADT + ARPI vs cont ARPI + ADT + Doce 🔷Prim EP: OS 🚨 Important RCT for subopt PSA

Breaking news ASCO #ASCO25 👉 1st biomarker selected, positive ph3 trial in mHSPC #ProstateCancer 👉Abiraterone+ niraparib/PARPi significant improve rPFS (favorable OS trend) in HRR+ pts (⬆️benefit in BRCApts), NGS testing must inall AttardLab PCF Science UroToday.com OncoAlert

#FDA approves darolutamide for metastatic castration-sensitive #prostatecancer U.S. FDA ASCO Advanced Prostate Cancer Consensus Conference OncoAlert #ASCO25 Uromigos Oncology Brothers